TC
BOLT icon

T3 Companies’s Bolt Biotherapeutics BOLT Stock Holding History

T3 Companies’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$146K Hold
38,000
– – 0.16% 104
2026
Q1 		$154K Hold
38,000
– – 0.2% 71
2025
Q4 		$208K Buy
+38,000
New +$204K 0.26% 81

Other funds holding BOLT

SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

T3 Companies's BOLT Position: Q2 2026 in Review

T3 Companies held its Bolt Biotherapeutics (BOLT) position steady in Q2 2026 at 38,000 shares worth $146K. The position accounts for 0.16% of the portfolio, ranked #104.

T3 Companies first reported a position in BOLT in Q4 2025 and has held it in 3 quarters since. The position peaked at $208K in Q4 2025. 23 funds tracked by Wall St. Rank hold BOLT as of Q2 2026.

  • T3 Companies held 38,000 shares of Bolt Biotherapeutics worth $146K as of Q2 2026.
  • T3 Companies left its Bolt Biotherapeutics share count unchanged in Q2 2026.
  • Bolt Biotherapeutics made up 0.16% of T3 Companies's portfolio in Q2 2026, its #104 holding.
  • T3 Companies first reported a position in Bolt Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • T3 Companies's Bolt Biotherapeutics position peaked at $208K in Q4 2025.
  • 23 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2026.

Based on T3 Companies's 13F filing for Q2 2026, filed 27 Jul 2026.